PMID- 29190949
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210103
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 54
DP  - 2017 Nov 3
TI  - Association between PD-L1 expression combined with tumor-infiltrating lymphocytes 
      and the prognosis of patients with advanced hypopharyngeal squamous cell 
      carcinoma.
PG  - 92699-92714
LID - 10.18632/oncotarget.21564 [doi]
AB  - Limited information is available regarding the immune-related prognostic factors 
      of patients with advanced hypopharyngeal squamous cell carcinoma (HPSCC). The 
      expression of programmed cell death-ligand 1 (PD-L1) in tumor cells contributes 
      to a mechanism that allows cancer cells to escape immune surveillance. We 
      investigated whether PD-L1 or human leukocyte antigen (HLA) class I expression in 
      tumor cells and the tumor-infiltrating lymphocyte (TIL) density were associated 
      with the tumor response to neoadjuvant chemotherapy (NAC) and survival in 
      patients with advanced HPSCC. We retrospectively reviewed 83 consecutive patients 
      with stage III or IV HPSCC who received NAC. We evaluated PD-L1 and HLA class I 
      expression and TIL density using immunohistochemistry. Univariate and 
      multivariate analyses demonstrated that CD8(+) TIL density was an independent and 
      significant predictive factor for the response to NAC, progression-free survival 
      (PFS) and overall survival (OS), whereas PD-L1 or HLA class I expression did not 
      significantly correlate. The subgroup analysis revealed that a higher CD8(+) TIL 
      density without detectable PD-L1 expression tended to be associated with longer 
      patient survival. These results suggest that PD-L1 expression levels combined 
      with CD8(+) TIL density may serve as a predictive biomarker for patients with 
      stage III or IV HPSCC receiving NAC.
FAU - Ono, Takeharu
AU  - Ono T
AD  - Department of Otolaryngology-Head and Neck Surgery, Kurume University School of 
      Medicine, Kurume, Japan.
FAU - Azuma, Koichi
AU  - Azuma K
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Kawahara, Akihiko
AU  - Kawahara A
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Sasada, Tetsuro
AU  - Sasada T
AD  - Cancer Vaccine Center, Kanagawa Cancer Center Research Institute, Yokohama, 
      Japan.
FAU - Hattori, Satoshi
AU  - Hattori S
AD  - Biostatistics Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Sato, Fumihiko
AU  - Sato F
AD  - Department of Otolaryngology-Head and Neck Surgery, Kurume University School of 
      Medicine, Kurume, Japan.
FAU - Shin, Buichiro
AU  - Shin B
AD  - Department of Otolaryngology-Head and Neck Surgery, Kurume University School of 
      Medicine, Kurume, Japan.
FAU - Chitose, Shun-Ich
AU  - Chitose SI
AD  - Department of Otolaryngology-Head and Neck Surgery, Kurume University School of 
      Medicine, Kurume, Japan.
FAU - Akiba, Jun
AU  - Akiba J
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Hirohito, Umeno
AU  - Hirohito U
AD  - Department of Otolaryngology-Head and Neck Surgery, Kurume University School of 
      Medicine, Kurume, Japan.
LA  - eng
PT  - Journal Article
DEP - 20171006
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5696215
OTO - NOTNLM
OT  - CD8+ TILs
OT  - PD-L1
OT  - hypopharyngeal squamous cell carcinoma
OT  - immunohistochemistry
OT  - neoadjuvant chemotherapy
COIS- CONFLICTS OF INTEREST The authors declare that there are no conflicts of 
      interest.
EDAT- 2017/12/02 06:00
MHDA- 2017/12/02 06:01
PMCR- 2017/11/03
CRDT- 2017/12/02 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/02 06:01 [medline]
PHST- 2017/11/03 00:00 [pmc-release]
AID - 21564 [pii]
AID - 10.18632/oncotarget.21564 [doi]
PST - epublish
SO  - Oncotarget. 2017 Oct 6;8(54):92699-92714. doi: 10.18632/oncotarget.21564. 
      eCollection 2017 Nov 3.